Effectiveness of Cryotherapy Combined With Compression Therapy for Preventing Chemotherapy-induced Peripheral Neuropathy
Recruiting now · Not applicable
Conditions studied: Breast Cancer
In brief
This is a prospective, multi-center, randomized study designed to evaluate the clinical efficacy of cryotherapy combined with compression therapy in preventing albumin-paclitaxel induced peripheral neuropathy.
Key facts
- Study ID
- NCT05341141
- Run by
- Peking University
- People needed
- 102
- Starts
- 2022-06-10
- Expected to finish
- 2026-11-01
- Last updated by the study team
- 2022-06-13
Who can join
Age: 20 and older, up to 70. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Female patients aged from 20 to 70 years old;
- Histologically confirmed as invasive breast cancer;
- HER-2 negative (defined by IHC 0 or 1+ ,or FISH negative);
- Participants who meet any of the following conditions: 1) T > 2 cm, ER<1% and PR<1%; 2) T > 2 cm, ER≥1% and biopsy pathology (FNAB or CNB) diagnosed regional lymph node metastasis;
- Without any previous treatment;
- ddEC-ddT neoadjuvant chemotherapy is planned;
- Participants must have at least one measurable disease according to RECIST 1.1;
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
- LVEF ≥ 50%;
- The ECG results are judged to be almost normal or normal, or the investigator judges that the abnormalities are not clinically significant;
- Bone marrow function: absolute neutrophil counts (ANC) ≥ 1.5x10\^9/L, platelets ≥ 100x10\^9/L, hemoglobin ≥ 90g/L;
- Liver and kidney function: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are both ≤2.5 ULN; serum total bilirubin and serum creatinine are both ≤ 1.5 ULN;
- Participants had good compliance with the planned treatment and follow-up, understood the study procedures of this study, and signed informed consent form.
You may not qualify if…
- Breast cancer with distant metastasis;
- A history of other malignancies;
- In the past or present, participants with sensory or motor neurological diseases;
- Participants who are known to be allergic to the active or other components of the study treatment;
- Cerebral thrombosis is present;
- In the past and present, participants with severe cardiac disease or discomfort , including but not limited: 1) High-risk uncontrolled arrhythmia, atrial tachycardia (heart rate > 100/min in resting state), significant ventricular arrhythmia (ventricular arrhythmia) or higher atrioventricular block (second-degree type 2 [Mobitz 2] atrioventricular block or third-degree atrioventricular block); 2) Angina pectoris requiring anti-angina medication; 3) Clinically significant valvular heart disease; 4) ECG showing transmural myocardial infarction; 5) ncontrolled hypertension (eg systolic blood pressure > 180mm Hg or diastolic blood pressure > 100mmHg); 6) Myocardial infarction; 7) Congestive heart failure;
- Participants have the following serious illnesses or medical conditions, including but not limited: 1) History of serious neurological or psychiatric disorders, including psychosis, dementia, or epilepsy, that prevent understanding and informed consent; 2) Active uncontrolled infection; 3) Active pepticulcer, unstable diabetes;
- Participants who are pregnant, breastfeeding, or refuse to use adequate contraception prior to study entry and for the duration of study participation;
- Participants who were judged by the investigator to be unsuitable for this study.
Where it is running
- Peking University Cancer Hospital — Beijing, Beijing Municipality, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.